Cell-free RNA, including both long RNA and small RNA, has been considered important for its biological functions and potential clinical usage, but the major challenge is to effectively sequence them at the same time. Here we present PolyAdenylation Ligation Mediated-Seq (PALM-Seq), an integrated sequencing method for cell-free long and small RNA. Through terminal modification and addition of 3' polyadenylation and 5' adaptor, we could get mRNA, long non-coding RNA, microRNA, tRNA, piRNA and other RNAs in a single library. With target RNA depletion, all these RNAs could be sequenced with relatively low depth. Using PALM-Seq, we identified pregnant-related mRNAs, long non-coding RNAs and microRNAs in female plasma. We also applied PALM-Seq to sequence RNA from amniotic fluids, leukocytes and placentas, and could find RNA signatures associated with specific sample type. PALM-Seq provides an integrated, cost-effective and simple method to characterize the landscape of cell-free RNA, and can stimulate further progress in cell-free RNA study and usage.
Results

Principle of PALM-Seq.
For amount of cfRNA was low, in order to avoid RNA degradation or adsorption to the tube, 3' polyadenylation was added by E. coli Poly(A) Polymerase (PAP) 16 in the first step. The terminal modification of cfRNA was different, however T4 Polynucleotide Kinase (T4 PNK) could make most part of them to 5' end phosphorylated and 3' end hydroxyl 17, 18 except those with 5' cap. Because T4 PNK and PAP could work in the same buffer with ATP, separate step of pretreatment for cfRNA with T4 PNK was unnecessary. Then, 5' adaptor was then ligated by T4 RNA Ligase 1 19 . In contrast to 3' DNA adaptor used in common small RNA seq, 3' polyadenylation could not be degraded by DNase I which was necessary for RNase H method 20 . So, rRNA or other uninterested, abundant RNA could be easily removed by RNase H method. DNase I treatment could also prevent the possible contamination of cell-free DNA. Finally, RNA with 3' polyadenylation and 5' adaptor was reverse transcribed by oligo(dT) with 3' adaptor and amplified by PCR ( Fig. 1a ). Most part of the library was short fragments as expected. The processing pipeline of sequencing data was shown in Fig. 1b .
In order to test the effect of T4 PNK treatment (PNKT) and target depletion (TD) which was performed through RNase H method, and identify the best work condition for cfRNA, we used four samples, each of which was treated in four work conditions, with or without PNKT and with or without TD. We also wanted to know whether TD could remove other abundant RNA, so Y RNA and Vault RNA which were rich in plasma cfRNA 21 and not interested in this study, were also depleted for plasma samples.
PALM-Seq could capture plasma mRNA, lncRNA and small RNA with high complexity.
Complexity is especially important for low-quantity and low-quality RNA sequencing 20, 22 , and it is better to get more kinds of RNA in one library. To assess the performance of different treatments and methods, we analyzed the data to account for differences in number of different genes detected and contribution of different kinds of RNA. PALM-Seq with PNKT (TD or no TD) could detect larger number of mRNA To further qualify our method, we referred to public data produced by SMARTer Seq (by using Clontech SMARTer Stranded Total RNA-Seq Kit -Pico) 15 , ScriptSeq (by using Illumina ScriptSeq v2 Kit) 23 and Small RNA Seq (by using NEBNext Small RNA Library Preparation Kit) 24 to quantify if PALM-seq was comparable or even better. While SMARTer Seq and ScriptSeq were designed for large fragment RNA, they were effective to detect mRNA or lncRNA ( Fig. 2a-b ), but they could not cover small RNA ( Fig. 2c-e ). In contrast, Small RNA Seq performed well in detecting miRNA ( Fig. 2c ), but was not suitable for lncRNA or mRNA ( Fig. 2a-b ). RNA ratio also showed that mRNA and lncRNA were rich in PALM-Seq with PNKT (TD or no TD), SMARTer Seq or ScriptSeq, however miRNA was rich in PALM-Seq with no PNKT (TD or no TD) or Small RNA Seq (Fig. 2f ). In addition, tRNA and piRNA ratio was higher in PALM-Seq ( Fig. 2f ).
Length contribution of different sort of RNA were also checked to further estimate the effect of PNKT. Large fragments of mRNA or lncRNA could be captured without PNKT, however, more small fragments of mRNA or lncRNA would be captured with PNKT, for small fragments might be produced by RNase (e.g. RNase A) with 3' phosphorylated and 5' hydroxyl. Length contribution of small RNA were less influenced by PNKT. The information provided by small fragments of mRNA or lncRNA would be important especially for small amount or long-stored samples without enough long fragments, so PNKT was acquired for mRNA or lncRNA analysis.
These results illustrated that PALM-Seq could be used for miRNA, tRNA and piRNA whether with or without PNKT, but PNKT was necessary for mRNA and lncRNA analysis.
TD could remove uninterested RNA efficiently and improve mapping rate.
Mapping rate is important for data analysis to detect more genes, splicing or other variations with lower sequencing depth 20 . Depletion of uninformative abundant RNA (e.g. rRNA) can increase mapping rate and maximize the coverage of other transcripts present in a sample. To test the efficiency and necessity of TD, we calculated rRNA ratio ( Fig. 3a ). We found that rRNA could be removed efficiently by TD, especially in PNKT condition, otherwise, the rRNA ratio would be extremely high. In no PNKT condition, TD was dispensable. In addition, Y RNA and Vault RNA could also be removed by TD. SMARTer Seq removed rRNA through CRISPR, so the rRNA ratio was low, but ScriptSeq or Small RNA Seq data contained high ratio of rRNA.
To further estimate informative data ratio, we calculated mRNA, lncRNA and miRNA mapping rate to total reads ( Fig. 3b-d ). We found that TD increased mRNA and lncRNA mapping ratio ( Fig. 3b -c) and decreased the acquired sequencing depth 25 when PNKT was used ( Fig. 3e-f ). However, TD did not significantly influence miRNA mapping ratio.
Then we compared mapping rate among different methods. For mRNA and lncRNA mapping rate, PALM-Seq with PNKT and TD performed similarly with SMARTer Seq, and much better than Small RNA Seq. ScriptSeq performed best for mRNA but not well for lncRNA. For miRNA mapping rate, PALM-Seq with PNKT and TD performed similarly with Small RNA Seq, although lower than PALM-Seq with no PNKT and no TD.
These results suggested that TD was helpful, and it was necessary when PALM-Seq was used to detect both mRNA and miRNA, for rRNA ratio might be unacceptable if only PNKT was used.
We recommended PALM-Seq with PNKT and TD for the studies which needed both mRNA/lncRNA and miRNA, and PALM-seq with no PNKT and no TD for the researches focused on miRNA.
Because both mRNA/lncRNA and miRNA were needed in our further work, PALM-Seq with PNKT and TD were used for other samples mentioned in this study.
PALM-Seq was a robust method for plasma RNA-Seq.
An ideal cfRNA sequencing method should not only display high yield, complexity and mapping rate, but also have high reproducibility 22 . We tested the reproducibility of PALM-Seq and found that PALM-Seq with PNKT and TD showed the similar consistency for mRNA as SMARTer Seq or ScriptSeq ( Fig. 4a ), but the consistency of lncRNA was higher for PALM-Seq ( Fig. 4b ). PALM-Seq with PNKT and TD or PALM-Seq with no PNKT and no TD gave more stable results compared with Small RNA Seq (Fig. 4c ).
Coverage metrics might be critical for certain measurements. We calculated the variation in coverage of mRNA and lncRNA from 5' to 3' 20 , and PALM-Seq did not show significant bias from 5' to 3' by considering all detected genes. We then aligned the small RNAs to their respective precursors 26 . As expected, the mature miRNAs were aligned to the two arms of the pre-miRNA hairpins (Fig. 4f ). The tRNA-derived small RNAs (tsRNAs) were mainly derived from the two regions of the mature tRNA, but it showed slight difference with cell tsRNAs 26 (Fig. 4g ).
To estimate the failure rate of this method, we totally built 120 libraries for plasma cfRNA, and 2 of them failed for low yield (<300ng).
For further usage of PALM-Seq, we assessed the influence of sequencing depth 25 and read length. First, we evaluated saturation plots for different transcript biotypes. It was shown that 20M clean reads (about 40M total reads) were enough for mRNA, lncRNA, miRNA and tRNA quantification. Due to the low piRNA ratio, more reads might be acquired for piRNA analysis. We then compared expression results with single read 35 cycles or 100 cycles, and there was no significant difference, because most of cfRNA fragments were short.
Placental-specific genes could be detected in plasma cfRNA from pregnant women.
One of the basic usages for RNA-Seq is differentially expressed gene (DEG) analysis 27 , so PALM-Seq was tested for DEGs. During pregnancy, placenta releases nucleic acids into blood. To test whether PALM-Seq could capture placental specific RNA, we collected blood samples from 4 nonpregnant females and 4 pregnant females (three time points: 12, 24 and 36 gestational week).
Principal components analysis 28 (PCA) showed that there were no significant outliers. Then, we checked the expression of placenta-specific mRNA/lncRNA ( Fig.   5a ) or miRNA ( Fig. 5b ). As expected, these genes were only expressed in plasma from pregnant women. We verified 5 mRNA/lncRNA genes and 5 miRNAs. Protein coding gene such as CGA, CSH1 and CSH2, and long non-coding gene such as PLAC4 15 , were very low or undetected in nonpregnant females, and increased during pregnancy. S100A8 which are related to pregnant immunomodulation 15 , also increased ( Fig. 5c ). Placental-specific C17MC miRNA 29 such as mir-526b-5p, mir-519d-3p, mir-515-5p and mir-512-3p, also existed in plasma of pregnant females;
and we found mir-454-3p decreased (Fig. 5d ). These results were validated by RT-qPCR ( Fig. 5c-d ). Together with the results above, it was suggested that PALM-Seq could provide reliable results for DEG analysis.
Discussion
Although the kits designed for total RNA such as Ribo-Zero Gold Kit NuGen's 13 or RNA-Seq Ovation System Kit 14 , were used before, they are not proper for cell-free RNA. Now, Small RNA Seq, SMARTer Seq and ScriptSeq are considered as optimized choices 15, [22] [23] [24] . However, Small RNA Seq method requires 5' phosphorylated and 3' hydroxyl 36 
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Figure 3 | Mapping rate of different cfRNA sequencing methods. a-d,
Performance of each library with respect to rRNA ratio (a, normalized to read number after low-quality reads and <17bp reads have been filtered), mRNA mapping rate (b, normalized to total read number), lncRNA mapping rate (c, normalized to total read number) and miRNA mapping rate (d, normalized to total read number). Unpaired two-sided Student's t-test is used to assess significance. The original p values are shown here. e-f, Saturation plots for mRNA (e) and lncRNA (f) shows the influence of TD to the acquired sequencing depth when PNKT is used.
Figure 4 | Reproducibility and transcript coverage of PALM-Seq. a-c,
Reproducibility is measured by coefficient of determination (R 2 ). PALM-Seq with PNKT and TD is compared with SMARTer-Seq or ScriptSeq for mRNA (a) and lncRNA (b). PALM-Seq with PNKT and TD or with no PNKT and no TD are compared with Small RNA Seq for miRNA (c). R 2 is calculated through simple linear regression of log 2 (TPM+1) for mRNA and lncRNA or log 2 (RPM+1) for miRNA. d-e, Normalized coverage by position for mRNA (d) and lncRNA (e). For each library, the average relative coverage is shown at each relative position along the transcripts' length. f-g, Coverage of miRNA (f) and tRNA-derived small RNAs (tsRNA, g) across the length of the precursor RNAs (divided into 40 bins). Different curves stand for different samples using PALM-Seq with PNKT and TD. PSG1  FLT1  VGLL3  PSG5  GDF15  PAPPA  ADAM12  SLC6A4  PDGFB  SH3TC2  CYP19A1  SERPINE1  SERPINE2  FN1  KISS1  PSG3  PSG4  PSG9  CGB8  PSG2  PRG2  HSD3B1  TFAP2A  CSHL1  LGALS14  F5  MYCN  EBI3  PAPPA2  CRH  HTRA4  ISM2  PEG10  SVEP1  CAPN6  GPC3  EGFR  BMP6  P2RY1  TFPI2  CSH2  TMEM40  CSH1  IGF2  CGA   0   1   2   3   4   5   6   7 log2(TPM+1) 
